Tempus AITEM
Recorded

Tempus AI 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration41 minParticipants13

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Hello, everyone. Thank you for joining us, and welcome to Tempus Q3 2026 financial results call. After today's prepared remarks, we will host a question-and-answer session. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again. I will now hand the conference over to Kendra Webster, VP of Investor Relations. Please go ahead. Thank you, Matt.

Kendra WebsterVP of Investor Relations

Good morning, and welcome to Tempus' third quarter 2026 conference call. This morning, Tempus released results for the quarter ended September 30, 2026. The press release, overview of the quarter, and our latest presentation are available on our IR website at investors.tempus.com. Joining me today are Eric Lefkofsky, founder and CEO of Tempus, and Jim Rogers, CFO. Before we begin, I would like to remind you that during this call, management will be making forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially. For a discussion of these risks, please refer to our 10-K and other subsequent filings with the SEC. During the call, we will discuss non-GAAP financial measures, which are not prepared in accordance with generally accepted accounting principles.

Kendra WebsterVP of Investor Relations

Definitions of these non-GAAP financial measures, along with reconciliations to the most directly comparable GAAP financial measures, are included in our earnings release, which is available on our IR page. I will now turn the call over to Eric.

Eric LefkofskyFounder and CEO

Q3 was an incredibly strong quarter for Tempus, with broad-based growth across both our diagnostics and data and applications businesses. Momentum from the first half of 2026 carried into the third quarter, with total revenue of $411.5 million, increasing 23% year-over-year, led by accelerating unit growth of 32% in our oncology business and increasing momentum of 33% revenue growth in data and apps. Our diagnostics business delivered $303.5 million of revenue, an increase of 20% year-over-year, driven by oncology revenues, which grew 28%, with volume growth of 32%, as we continue to see some of the strongest unit volume growth we have seen in years. Oncology revenues were $172.6 million, and hereditary cancer testing revenues were $111.3 million.

Eric LefkofskyFounder and CEO

Data and apps revenues were $108.1 million, increasing 33% year-over-year, as that business continues to outperform, led by Insights, our data licensing segment, which grew 29%. These results reinforce the durability of our model as our best-in-class diagnostic platform enhances our data and AI offerings, distinguishes our business from our many competitors, and helps drive the performance we have delivered consistently quarter after quarter. There were also several notable highlights since our last quarterly call. We entered into a strategic collaboration with Bristol Myers Squibb, or BMS, whereby we agreed to license BMS oncology data and models for up to $137.5 million over a five-year term. Additionally, BMS, Pathos, and Tempus have entered into a collaboration to build datasets and models for Alzheimer's disease. Through this collaboration, Pathos is paying Tempus $55 million over a five-year term.

Eric LefkofskyFounder and CEO

As a result, over the next approximately five years, we expect to generate $192.5 million of additional data and applications revenue from these agreements alone. This is one of our largest strategic collaborations to date, and it's nice to see BMS join the likes of AstraZeneca, Merck, GlaxoSmithKline, and BioNTech. As I've said before, if we sign just one of these big collaborations, we would be content. We've signed three this year alone. We announced a multi-year strategic collaboration with Moderna and Merck to support the potential commercialization of their novel first-in-class individualized neoantigen therapy, or INT, being evaluated in combination with KEYTRUDA in patients with completely resected stage IIB to IV melanoma and other cancer types.

Eric LefkofskyFounder and CEO

Given the exceptional response of the clinical trial data so far and the potential for this drug to be transformational, we are excited by the future of this program and thrilled to be partnering with Moderna and Merck. We cleared regulatory review of our pending acquisition of Personalis, and a Personalis shareholder meeting to approve the transaction is scheduled for November 30th. We are more convinced than ever of the synergies between our combined companies. We have been the exclusive distributor of Personalis' tumor-informed MRD assay, NeXT, since 2023, which we believe is a best-in-class assay given its ultra-sensitivity. MRD represents an estimated $20-plus billion market and is one of the fastest-growing segments in oncology diagnostics. It is transformative for cancer care, allowing clinicians to detect disease recurrence earlier than traditional imaging, enabling more informed treatment decisions when cancer recurs.

Eric LefkofskyFounder and CEO

Bringing Personalis' testing portfolio under one roof will accelerate commercial adoption, round out our overall portfolio, and strengthen the multimodal data flywheel that continues to differentiate our business. We generated $25.6 million in Adjusted EBITDA and ended the quarter with $854.4 million in cash and marketable securities. We had long suspected that with gross profit dollar growth outpacing our investments, we would eventually turn the corner and be able to generate meaningful EBITDA. This quarter, we made the turn. Despite our increasing investments in diagnostics, we have always been a tech company. Our entire business model was built around the idea of collecting vast amounts of real-time, multimodal, de-identified data to both improve clinical decisions and enhance research.

Eric LefkofskyFounder and CEO

A decade later, those efforts have allowed us to amass more than 600 petabytes of rich data, adding more than 50 petabytes last quarter alone, along with the technology infrastructure that is connected to approximately 8,000 providers, enabling us to use that data to train models and generate Insights. The scale of our business and the breadth of our portfolio has allowed us to build a significant data moat. By compounding a decade of investment in our AI capabilities, we deliver solutions that grow more powerful with every patient touchpoint, cementing our position as an indispensable engine for healthcare innovation. As the world gets hungrier for the benefits AI can deliver, namely allowing people to live longer and healthier lives, Tempus is uniquely positioned as we have strategically amassed the data needed to power these models and the distribution platform to deliver them to patients.

Eric LefkofskyFounder and CEO

As a result of our financial performance this quarter, we are increasing guidance to $1.60 billion-$1.605 billion in 2026. We continue to expect 2026 Adjusted EBITDA to be approximately $65 million. With that, we will open it up to questions.

Operator

We will now begin the question-and-answer session. Please limit yourself to one question. If you'd like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again. We ask that you pick up your handset when asking a question to allow for optimum sound quality. If you are muted locally, please remember to unmute your device. Please stand by while we compile the Q&A roster. Your first question comes from the line of Kyle Mikson with Canaccord Genuity. Kyle, your line is open. Please go ahead. Hey, guys.

Kyle MiksonAnalyst

Thanks for the questions. Congrats on the quarter. One question on hereditary. You're hoping that returns to stable growth next year, but just given these proposed Clinical Lab Fee Schedule rates that factor in PAMA cuts, I'm just wondering how you're thinking about potential headwinds there, given, then obviously you have ASP tailwinds on the oncology side, so maybe just talk about diagnostics outlook for 2027.

Eric LefkofskyFounder and CEO

Yeah. Hey, I can start. I think the overall hereditary business seems to be poised to do much better as we move forward than it has over the last few quarters, in large part because it's both lapping excessive growth last year, which we've talked about relative to some of the market dynamics where you had a big player in the market that was having some financial issues, a bunch of volume moved over. Instead of nice, even, whatever, near 15% growth year after year, you had this like jump up to 30% growth that we're now lapping. We've seen some good sign of that in September and October, where unit growth rates have returned to low double digits.

Eric LefkofskyFounder and CEO

We feel overall like that business is moving in a better direction, and that whatever macro headwind there is in terms of guidance is small compared to the just massive unaddressed TAM relative to the fact that current guidelines and current reimbursement would cover about 70 million lives, and in the U.S., we run something like 2 million tests a year. I think we still have a very under-penetrated market. I suspect as more and more literature comes out finding clear links between germline variants and diseases that can be prevented or managed earlier, you'll see this category continue to be stable and grow. Jim can cover ASPs on the oncology side.

Jim RogersCFO

Yeah. On ASPs for hereditary, just as a reminder, obviously hereditary cancer makes up the majority of that revenue, but we do have a small but growing rare business. We don't anticipate material impacts from PAMA on the hereditary cancer rates. We've long said that the hereditary rates for us will actually probably increase slightly over time as rare becomes a bigger piece of the overall pie. That's the story on ASPs for hereditary. On the oncology side, as we've talked about, given the expansion of our FDA approval to include tumor only for our xT test, that updated pricing will kick in on January 1st and allow us to move the remaining xT volume over. That gives us about $80 million of uplift in oncology ASP in 2027.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day